Biologics that target GM-CSF for COVID-19 pneumonia or ARDS are actively being investigated in clinical trials, including TJ003234 (NCT04341116), Lenzilumab (NCT04351152), Gimsilumab (NCT04351243) and Mavrilimumab (NCT04447469) [34]. This evidence concerns the gene CSF2 and acute respiratory distress syndrome.